SynAct Pharma : has successfully completed the bookbuilding procedure - directed issues provide the company with a total ...
Background and motive to the Directed Issues The proceeds from the Directed Issues will enable the Company to continue the development in a Phase 2b study in RA with the Company's lead asset resomelagon. The planned study is a dose-determining proof-of …